5.78
+0.02(+0.35%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
498
First IPO Date
February 23, 2022
| Name | Title | Pay | Year Born |
| Dr. Ziye Sui M.D., Ph.D. | Chief Executive Officer & Director | 2.7M | 1981 |
| Dr. Zhongjie Pu | Executive Chairman | 0 | 1963 |
| Ms. Lixuan Zhao | Supervisor & Investor Relations Director | 0 | 1992 |
| Ms. Yunyi Li | Chief Financial Officer & Board Secretary | 0 | 1980 |
| Ms. Siu Kuen Lai FCIS, FCS | Joint Company Secretary | 0 | 1976 |
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.